About 400 reports

Boehringer Sohn AG & Co KG - Abbott Laboratories - AbbVie Inc Human Immunodeficiency Virus (HIV) Infections (AIDS) Global Clinical Trials Review, H##, 2017 Summary GlobalData’s clinical trial report, “Human Immunodeficiency Virus (HIV) Infections (AIDS) Global

  • Clinical Trial
  • HIV AIDS
  • Pathology
  • Therapy
  • World
  • SOURCES

Understanding HIV/ AIDS: The HIV Lifecycle.

  • HIV AIDS
  • United States
  • Gilead Sciences, Inc.
  • Janssen Biotech, Inc.
  • ViiV Healthcare Ltd.

APPROXIMATELY ##% OF HIV/ AIDS PATIENTS IN DEVELOPING COUNTRIES DEPEND ON MYLAN' S ANTIRETROVIRAL THERAPIES.

  • HIV AIDS
  • Canada
  • North America
  • United States
  • Mylan Inc.
  • 2.2 Human Immunodeficiency Virus (HIV)

ABOUT HIV/ AIDS.

  • HIV AIDS
  • Therapy
  • World
  • Market Size
  • Gilead Sciences, Inc.

Research and Development Brief Fixed Dose Combination ## for HIV Product Description Fixed dose combination for HIV is under development.

  • HIV AIDS
  • United States
  • Auspex Pharmaceuticals, Inc.
  • Cephalon, Inc.
  • ChemGenex Pharmaceuticals Limited
  • RISK FACTORS & PREVENTION
  • REFERENCES

Black Swan Analysis Epiomic™ Epidemiology Series Forecast Report on HIV in 8 Major Markets The human immunodeficiency virus (HIV) is a lentivirus that causes chronic viral infection. HIV damages the immune system and prevents the body from fighting off the organisms that cause infection and disease. Without early diagnosis and...

  • HIV AIDS
  • Pathology
  • HIV / AIDS - Dormant Projects
  • HIV / AIDS - Recent Pipeline Updates

HIV / AIDS - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘HIV / AIDS - Pipeline Review, H2 2015’, provides an overview of the HIV / AIDS’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for HIV / AIDS, complete with comparative analysis at various...

  • HIV AIDS
  • Vaccine
  • United States
  • Company Operations
  • Gilead Sciences, Inc.
  • VACCINE FOR ONCOLOGY AND HIV/AIDS - DRUG PROFILE
  • VIRUS (HIV) INFECTIONS (AIDS)

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H2 2017, provides an overview of the Human Immunodeficiency...

  • Healthcare
  • HIV AIDS
  • Pathology
  • Vaccine
  • Merck & Co., Inc.

The estimated number of people suffering from HIV in 2015 was recorded to be more than ## million according to AVERT, a UK-based HIV and AIDS charity.

  • HIV AIDS
  • Therapy
  • United States
  • Forecast
  • Market Size
  • SYNTHETIC PEPTIDE FOR HIV/AIDS - DRUG PROFILE
  • MONOCLONAL ANTIBODIES FOR HIV/AIDS - DRUG PROFILE

Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Human Immunodeficiency Virus (HIV) Infections (AIDS) - Pipeline Review, H1 2017, provides an overview of the Human Immunodeficiency Virus (HIV) Infections...

  • HIV AIDS
  • Vaccine
  • United States
  • Company
  • Product Initiative

II-## Worldwide HIV/ AIDS Testing Market - An Analysis II-## Regional Analysis..............

  • HIV AIDS
  • APAC
  • Japan
  • World
  • Company Sales

There are approximately ##, ## people living with HIV/ AIDS in China.

  • HIV AIDS
  • United States
  • Grifols, S.A.
  • Hologic, Inc.
  • Immucor, Inc.
  • HIV / AIDS - Dormant Projects
  • HIV / AIDS - Product Development Milestones

HIV / AIDS - Pipeline Review, H1 2016 Summary Global Markets Direct’s, ‘HIV / AIDS - Pipeline Review, H1 2016’, provides an overview of the HIV / AIDS pipeline landscape. The report provides comprehensive information on the therapeutics under development for HIV / AIDS, complete with analysis by stage of development,...

  • Gene Therapy
  • HIV AIDS
  • United States
  • Company
  • Product Initiative

Competitive Landscape ##. ## Antigen Express ##. ## Bionor Pharma ##. ## FIT Biotech ##. ## Gilead Sciences ##. ## GeoVax ##. ## GenVec ##. ## Glaxo Smithkline ##. ## Immune Response BioPharma ##. ## Inovio Pharmaceuticals ##. ## Novartis ##. ## Sanofi Pasteur List of Figures Figure ##-##: People Living With

  • HIV AIDS
  • Pathology
  • World

AIDS CASES).

  • HIV AIDS
  • China
  • Abbott Laboratories, Inc.
  • Immucor, Inc.
  • Roche Group

REASONS FOR DOING THE STUDY HIV/ AIDS is one of the most catastrophic threats to human health throughout the world.

  • HIV AIDS
  • Pathology
  • Therapy
  • World
  • Company Financials
  • Month & Year
  • CHINA DOMINATED THE ASIAN HIV DIAGNOSTICS MARKET IN 2016

The HIV diagnosis market is projected to reach USD 3.88 billion by 2021 from USD 2.35 billion in 2016, at a CAGR of 10.5% from 2016 to 2021. The global HIV diagnosis market is segmented based on product, test type, end user, and region. On the basis of product, the market is segmented into consumables (assays, kits, reagents, and other consumables),...

  • HIV AIDS
  • HIV Diagnostic
  • North America
  • United States
  • Market Size
  • PIPELINE BY INNAVIRVAX SA, H1 2016
  • Glycoprotein 41 (gp41) - Dormant Projects

Glycoprotein 41 (gp41) - Pipeline Review, H1 2018 Summary According to the recently published report ’Glycoprotein 41 (gp41) - Pipeline Review, H1 2018’; Glycoprotein 41 (gp41) pipeline Target constitutes close to 19 molecules. Out of which approximately 13 molecules are developed by companies and...

  • HIV AIDS
  • United States
  • World
  • Product Initiative
  • Mymetics Corporation
  • 9.9 HIV/AIDS
  • IVD MARKET SIZE FOR HIV/AIDS, BY COUNTRY, 2015-2022 (USD MILLION)

The IVD market in BRIC is expected to reach USD 15.71 billion by 2022 from USD 10.60 billion in 2017, at a CAGR of 8.2%. The key factors driving the growth of the market are growing patient awareness of personalized medicine, increasing prevalence of lifestyle and chronic diseases, growth in the number of private diagnostic centers, and improving...

  • HIV AIDS
  • Medical Device
  • North America
  • United States
  • Market Size
  • PIPELINE BY MYMETICS CORP, H2 2017
  • PRODUCTS UNDER DEVELOPMENT BY COMPANIES, H2 2017

Glycoprotein 41 (gp41) - Pipeline Review, H2 2017 Summary Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells. It is a subunit of the envelope protein complex of retroviruses. The interaction of gp41...

  • HIV AIDS
  • United States
  • World
  • Product Initiative
  • Mymetics Corporation

HIV Vaccine Market Opportunity & Clinical Pipeline Analysis ##.

  • HIV AIDS
  • Pathology
  • Vaccine
  • World
  • Social Conditions
  • Name
  • Mymetics Corp - Opportunities

Mymetics Corp (MYMX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations.The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The...

  • HIV AIDS
  • Pathology
  • Netherlands
  • Company Financials
  • Mymetics Corporation
  • Biotron Ltd - Opportunities
  • Biotron Ltd, History

Biotron Ltd (BIT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The...

  • HIV AIDS
  • Australasia
  • World
  • Company Financials
  • Biotron Limited
  • DORMANT PRODUCTS, H1 2018 (CONTD..1), H1 2018
  • PRODUCTS UNDER INVESTIGATION BY UNIVERSITIES/INSTITUTES, H1 2018

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Pipeline Review, H1 2018 Summary C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the...

  • HIV AIDS
  • United States
  • Company
  • Product Initiative
  • CytoDyn Inc.
  • PRODUCTS UNDER INVESTIGATION BY UNIVERSITIES/INSTITUTES, H2 2017
  • PIPELINE BY PHARIS BIOTEC GMBH, H2 2017

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) – Pipeline Review, H2 2017 Summary C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 12 molecules are developed by companies...

  • Chemokine
  • HIV AIDS
  • Therapy
  • United States
  • Product Initiative
  • PIPELINE BY TAIMED BIOLOGICS INC, H1 2018
  • PIPELINE BY UNITED BIOMEDICAL INC, H1 2018

T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) - Pipeline Review, H1 2018 Summary T Cell Surface Glycoprotein CD4 (T Cell Surface Antigen T4/Leu 3 or CD4) pipeline Target constitutes close to 19 molecules. Out of which approximately 12 molecules are developed by companies...

  • HIV AIDS
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative
  • DEAL TYPE
  • EQUITY OFFERING

The company' s lead candidate, CAL-##, is being developed to prevent the progression of HIV to AIDS as a one-time treatment and is in phase I/ II clinical trials.

  • Biopharmaceutical
  • Healthcare
  • HIV AIDS
  • Therapy
  • Benitec Biopharma Limited
  • Apr 19, 2016: ABIVAX Obtains Regulatory and Ethics Clearance in Spain to Begin Second Phase IIa Clinical Trial For ABX464 In HIV/AIDS Patients
  • Jan 11, 2016: ABIVAX announces positive top-line clinical Phase IIa data for novel HIV drugcandidate ABX464

Summary Abivax SA (Abivax) is a biotechnology company that researches, develops and commercializes anti-viral therapies and therapeutic vaccines for the treatment of infectious diseases.The company’s pipeline products comprise ABX464, a small molecule against HIV; ABX311 for chikungunya; ABX544 to treat EBOLA virus infection;...

  • HIV AIDS
  • Pharmaceutical
  • France
  • Company
  • ABIVAX
  • Trans Activator Of Transcription (Tat) - Dormant Projects
  • Products under Investigation by Universities/Institutes, H2 2016

Trans Activator Of Transcription (Tat) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Trans Activator Of Transcription (Tat) - Pipeline Review, H2 2016’, provides in depth analysis on Trans Activator Of Transcription (Tat) targeted pipeline therapeutics. The report provides comprehensive information...

  • HIV AIDS
  • Vaccine
  • Turkey
  • Product Initiative
  • Cannabis Science, Inc.
  • NUMBER OF PRODUCTS UNDER DEVELOPMENT BY INDICATION, H2 2016
  • PIPELINE BY VIIV HEALTHCARE LTD, H2 2016

HIV 1 Integrase (EC 2.7.7.) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘HIV 1 Integrase (EC 2.7.7.) - Pipeline Review, H2 2016’, provides in depth analysis on HIV 1 Integrase (EC 2.7.7.) targeted pipeline therapeutics. The report provides comprehensive information on the HIV 1 Integrase (EC 2.7.7.)...

  • Antiviral
  • HIV AIDS
  • United States
  • Product Initiative
  • ViiV Healthcare Ltd.